Linked Life Data

12424538

Source:http://linkedlifedata.com/resource/pubmed/id/12424538

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12424538rdf:typepubmed:Citationlld:pubmed
pubmed-article:12424538lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12424538lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:12424538lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:12424538lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:12424538lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:12424538lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:12424538lifeskim:mentionsumls-concept:C0079459lld:lifeskim
pubmed-article:12424538lifeskim:mentionsumls-concept:C0023449lld:lifeskim
pubmed-article:12424538lifeskim:mentionsumls-concept:C0010711lld:lifeskim
pubmed-article:12424538lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:12424538lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:12424538lifeskim:mentionsumls-concept:C0086960lld:lifeskim
pubmed-article:12424538lifeskim:mentionsumls-concept:C0205421lld:lifeskim
pubmed-article:12424538lifeskim:mentionsumls-concept:C1554217lld:lifeskim
pubmed-article:12424538pubmed:issue10lld:pubmed
pubmed-article:12424538pubmed:dateCreated2002-11-8lld:pubmed
pubmed-article:12424538pubmed:abstractTextIn acute lymphoblastic leukemia (ALL), treatment with granulocyte colony stimulating factor (G-CSF) during remission induction shortens granulocytopenia and may decrease morbidity due to infections. However, the optimal timing of G-CSF administration after chemotherapy is not known. In a prospective randomized multi-center study, adult ALL patients were treated with high-dose ARA-C [HDAC, 3 g/m(2) bid (1 g/m(2) bid for T-ALL) days 1-4] and mitoxantrone (MI 10 mg/m(2) days 3-5). They were randomized to receive recombinant human G-CSF (Lenograstim) 263 micro g/day SC starting either from day 12 (Group 1) or day 17 (Group 2). Fifty-five patients (41 male, 14 female) with a median age of 34 years (range: 18-55 years) were enrolled into the study; 50 patients were evaluable. The median duration of neutropenia <500/ micro l after HDAC/MI was 12 days (range: 7-22 days) in the early G-CSF Group 1 and also 12 days (range: 4-22 days) in the late G-CSF Group 2; this was shorter than in the historical control group (15 days, range: 4-43 days, n=46) where the patients received identical cytotoxic treatment without G-CSF. Seventeen infections were observed in 14 patients in Group 1 (47%) and 13 infections in 10 patients in Group 2 (50%) compared to 27 infections in 49 patients of the historical control (54%). In Group 1, the patients received a median of 11 injections with G-CSF (range: 7-22) compared to 7 injections (range: 4-19) in Group 2. The total administered dose of G-CSF in Group 2 was significantly reduced by 40% ( P<0.0001). The delayed start of G-CSF after HDAC/MI in ALL achieves the same clinical benefit compared to the earlier initiation of G-CSF. The reduction of treatment costs by reducing the total G-CSF dose may be important in future treatment with this hematopoietic growth factor.lld:pubmed
pubmed-article:12424538pubmed:languageenglld:pubmed
pubmed-article:12424538pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12424538pubmed:citationSubsetIMlld:pubmed
pubmed-article:12424538pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12424538pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12424538pubmed:statusMEDLINElld:pubmed
pubmed-article:12424538pubmed:monthOctlld:pubmed
pubmed-article:12424538pubmed:issn0939-5555lld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:HoelzerDDlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:HartmannFFlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:SchottDDlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:RascheHHlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:FiedlerFFlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:HuberCClld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:FrankeAAlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:RudolphCClld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:BergmannLLlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:GanserAAlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:BalleisenLLlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:IlligerH JHJlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:PasoldRRlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:OttmannO GOGlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:SeipeltGGlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:PottCClld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:ReutzelRRlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:HofmannW KWKlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:GökbugetNNlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:SchoeffskiOOlld:pubmed
pubmed-article:12424538pubmed:authorpubmed-author:LangenhanSSlld:pubmed
pubmed-article:12424538pubmed:issnTypePrintlld:pubmed
pubmed-article:12424538pubmed:volume81lld:pubmed
pubmed-article:12424538pubmed:ownerNLMlld:pubmed
pubmed-article:12424538pubmed:authorsCompleteYlld:pubmed
pubmed-article:12424538pubmed:pagination570-4lld:pubmed
pubmed-article:12424538pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:meshHeadingpubmed-meshheading:12424538...lld:pubmed
pubmed-article:12424538pubmed:year2002lld:pubmed
pubmed-article:12424538pubmed:articleTitleProspective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.lld:pubmed
pubmed-article:12424538pubmed:affiliationDepartment of Hematology and Oncology, Johann Wolfgang Goethe University Hospital, Theodor-Stern-Kai 7, 60596 Frankfurt/Main, Germany. W.K.Hofmann@em.uni-frankfurt.delld:pubmed
pubmed-article:12424538pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12424538pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12424538pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:12424538pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12424538lld:pubmed